Revance Other Current Liab from 2010 to 2024

RVNC Stock  USD 3.80  0.07  1.88%   
Revance's Other Current Liabilities is increasing over the years with slightly volatile fluctuation. Overall, Other Current Liabilities is expected to go to about 56.5 M this year. During the period from 2010 to 2024 Revance Other Current Liabilities annual values regression line had geometric mean of  6,263,881 and mean square error of 183.7 T. View All Fundamentals
 
Other Current Liabilities  
First Reported
2011-12-31
Previous Quarter
23.3 M
Current Value
34 M
Quarterly Volatility
16.1 M
 
Yuan Drop
 
Covid
Check Revance financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revance's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 20.3 M or Total Revenue of 245.7 M, as well as many indicators such as Price To Sales Ratio of 3.02, Dividend Yield of 0.0 or Days Sales Outstanding of 41.0. Revance financial statements analysis is a perfect complement when working with Revance Valuation or Volatility modules.
  
Check out the analysis of Revance Correlation against competitors.
For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.

Latest Revance's Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Revance over the last few years. It is Revance's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revance's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Revance Other Current Liab Regression Statistics

Arithmetic Mean19,940,213
Geometric Mean6,263,881
Coefficient Of Variation108.88
Mean Deviation18,152,656
Median15,117,000
Standard Deviation21,710,620
Sample Variance471.4T
Range56.1M
R-Value0.80
Mean Square Error183.7T
R-Squared0.64
Significance0.0004
Slope3,878,134
Total Sum of Squares6598.9T

Revance Other Current Liab History

202456.5 M
202353.8 M
202254.4 M
202137.8 M
202031.6 M
201921.6 M
2018541 K

About Revance Financial Statements

Revance stakeholders use historical fundamental indicators, such as Revance's Other Current Liab, to determine how well the company is positioned to perform in the future. Although Revance investors may analyze each financial statement separately, they are all interrelated. For example, changes in Revance's assets and liabilities are reflected in the revenues and expenses on Revance's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Revance. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities53.8 M56.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Revance offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Revance's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Revance Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Revance Stock:
Check out the analysis of Revance Correlation against competitors.
For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revance. If investors know Revance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revance listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.34)
Revenue Per Share
2.656
Quarterly Revenue Growth
0.107
Return On Assets
(0.24)
Return On Equity
(20.97)
The market value of Revance is measured differently than its book value, which is the value of Revance that is recorded on the company's balance sheet. Investors also form their own opinion of Revance's value that differs from its market value or its book value, called intrinsic value, which is Revance's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revance's market value can be influenced by many factors that don't directly affect Revance's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revance's value and its price as these two are different measures arrived at by different means. Investors typically determine if Revance is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revance's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.